❌

Normal view

  • ✇MIT Technology Review
  • Building a high performance data and AI organization (2nd edition) MIT Technology Review Insights
    Four years is a lifetime when it comes to artificial intelligence. Since the first edition of this study was published in 2021, AI’s capabilities have been advancing at speed, and the advances have not slowed since generative AI’s breakthrough. For example, multimodality— the ability to process information not only as text but also as audio, video, and other unstructured formats—is becoming a common feature of AI models. AI’s capacity to reason and act autonomously has also grown, and organizati
     

Building a high performance data and AI organization (2nd edition)

Four years is a lifetime when it comes to artificial intelligence. Since the first edition of this study was published in 2021, AI’s capabilities have been advancing at speed, and the advances have not slowed since generative AI’s breakthrough. For example, multimodality— the ability to process information not only as text but also as audio, video, and other unstructured formats—is becoming a common feature of AI models. AI’s capacity to reason and act autonomously has also grown, and organizations are now starting to work with AI agents that can do just that.

Amid all the change, there remains a constant: the quality of an AI model’s outputs is only ever as good as the data
that feeds it. Data management technologies and practices have also been advancing, but the second edition of this study suggests that most organizations are not leveraging those fast enough to keep up with AI’s development. As a result of that and other hindrances, relatively few organizations are delivering the desired business results from their AI strategy. No more than 2% of senior executives we surveyed rate their organizations highly in terms of delivering results from AI.

To determine the extent to which organizational data performance has improved as generative AI and other AI advances have taken hold, MIT Technology Review Insights surveyed 800 senior data and technology executives. We also conducted in-depth interviews with 15 technology and business leaders.

Key findings from the report include the following:

• Few data teams are keeping pace with AI. Organizations are doing no better today at delivering on data strategy than in pre-generative AI days. Among those surveyed in 2025, 12% are self-assessed data “high achievers” compared with 13% in 2021. Shortages of skilled talent remain a constraint, but teams also struggle with accessing fresh data, tracing lineage, and dealing with security complexity—important requirements for AI success.

• Partly as a result, AI is not fully firing yet. There are even fewer “high achievers” when it comes to AI. Just 2% of respondents rate their organizations’ AI performance highly today in terms of delivering measurable business results. In fact, most are still struggling to scale generative AI. While two thirds have deployed it, only 7% have done so widely.

Download the report.

This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff. It was researched, designed, and written by human writers, editors, analysts, and illustrators. AI tools that may have been used were limited to secondary production processes that passed thorough human review.

Multi-omic profiling reveals age-related immune dynamics in healthy adults

Nature, Published online: 29 October 2025; doi:10.1038/s41586-025-09686-5

This multi-omic longitudinal analysis of the healthy human peripheral immune system constructs the Human Immune Health Atlas and assembles data on immune cell composition and state changes with age, including responses to cytomegalovirus infection and influenza vaccination.

Advancing Non-Small-Cell Lung Cancer Management Through Multi-Omics Integration: Insights from Genomics, Metabolomics, and Radiomics

Diagnostics (Basel). 2025 Oct 14;15(20):2586. doi: 10.3390/diagnostics15202586.

ABSTRACT

The integration of multi-omics technologies is transforming the landscape of cancer management, offering unprecedented insights into tumor biology, early diagnosis, and personalized therapy. This review provides a comprehensive overview of the current state of omics approaches, with a particular focus on the application of genomics, NMR-based metabolomics, and radiomics in non-small cell lung cancer (NSCLC). Genomics currently represents one of the most established omics technologies in oncology, as it enables the identification of genetic alterations that drive tumor initiation, progression, and therapeutic response. Interestingly, genomic analyses have revealed that many tumors harbor mutations in genes encoding metabolic enzymes, thus establishing a tight connection between genomics and tumor metabolism. In parallel, metabolomics profiling-by capturing the metabolic phenotype of tumors-has, in recent years, identified specific biomarkers associated with tumor burden, progression, and prognosis. Such findings have catalyzed growing interest in metabolomics as a complementary approach to better characterize cancer biology and discover novel diagnostic and therapeutic targets. Moreover, radiomics, through the extraction of quantitative features from standard imaging modalities, captures tumor heterogeneity and contributes predictive information on tumor biology, treatment response, and clinical outcomes. As a non-invasive and widely available technique, radiomics has the potential to support longitudinal monitoring and individualized treatment planning. Both metabolomics and radiomics, when integrated with genomic data, could support a more comprehensive understanding of NSCLC and pave the way for the development of non-invasive, predictive models and personalized therapeutic strategies. In addition, we explore the specific contributions of these technologies in enhancing clinical decision-making for lung cancer patients, with particular attention to their potential in early diagnosis, treatment selection, and real-time monitoring.

PMID:41153258 | DOI:10.3390/diagnostics15202586

Prospective proteomics for discovering biomarkers in lung adenocarcinoma: a literature review

Transl Cancer Res. 2025 Sep 30;14(9):6102-6117. doi: 10.21037/tcr-2025-1092. Epub 2025 Sep 26.

ABSTRACT

BACKGROUND AND OBJECTIVE: Lung adenocarcinoma (LUAD), as the main subtype of non-small cell lung cancer (NSCLC), faces clinical challenges including molecular heterogeneity, late diagnosis, and aggressive growth, leading to a low 5-year survival rate. Biomarkers are critical for early detection, accurate differentiation of benign/malignant lesions, and guiding personalized treatment strategies. Proteomic technologies using liquid biopsy show potential by analyzing protein changes and post-translational modifications (PTMs) to identify novel biomarkers and unravel cancer mechanisms. This review examines proteomic advances in LUAD, compares platform strengths, lists validated protein markers, and discusses challenges like specificity and regulations. It aims to develop a precision medicine framework by integrating multi-omics data for improved diagnosis and treatment.

METHODS: This study conducted a literature review by searching the PubMed and Web of Science databases for original articles written in English from 2002 to 2025, using the keywords "lung adenocarcinoma" OR "LUAD" AND "biomarkers" AND "proteomics" OR "SomaScan" OR "spatial proteomics" to identify the latest research findings in the field of proteomics technology and LUAD biomarkers. The included studies mainly focused on the current landscape of biomarkers in the diagnosis, treatment, and prognosis of LUAD.

KEY CONTENT AND FINDINGS: This review discusses high-throughput methods for comprehensive protein profiling in accessible biospecimens (tissues, blood, urine) to identify biomarkers for LUAD. We systematically evaluate emerging proteomic strategies, including mass spectrometry (MS), proximity extension assays (PEAs), spatial proteomics techniques, and SomaScan platforms-coupled with innovative computational frameworks have revolutionized biomarkers discovery and their translational potential in developing precision diagnostics and targeted therapies. Additionally, the review addresses challenges in integrating proteomics with genomics, transcriptomics, and metabolomics, offering new methodologies and expanding research in life sciences. As technological advancements continue, it is anticipated that more potential biomarkers will be conducted to validate the broader application in LUAD treatment, addressing early-stage disease complexities and aiding in selecting more effective treatment strategies.

CONCLUSIONS: By synthesizing cutting-edge evidence on proteome-driven LUAD biomarkers, this review elucidates actionable strategies to refine early detection protocols and mechanism-informed personalized treatment frameworks, directly advancing precision oncology initiatives for this prevalent malignancy through biomarker-guided clinical decision-making and multi-omics integration.

PMID:41158224 | PMC:PMC12554480 | DOI:10.21037/tcr-2025-1092

  • ✇STAT
  • STAT+: Natera, known for spotting cancer recurrence, wades into early detection Elaine Chen
    Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It seems everyone I know has been getting sick lately — hope you are all taking care of yourselves! Onto the news today. BridgeBio notches another Phase 3 win BridgeBio said this morning that its investigational drug succeeded in a late-stage trial of patients with autosomal dominant hypocalcemia type 1, a rare genetic condition that causes low calciu
     

STAT+: Natera, known for spotting cancer recurrence, wades into early detection

29 October 2025 at 21:26

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. It seems everyone I know has been getting sick lately — hope you are all taking care of yourselves! Onto the news today.

BridgeBio notches another Phase 3 win

BridgeBio said this morning that its investigational drug succeeded in a late-stage trial of patients with autosomal dominant hypocalcemia type 1, a rare genetic condition that causes low calcium levels in the blood.

Continue to STAT+ to read the full story…

© Adobe

Improving Recruitment Into Research Studies via Electronically Collected Patient-Entered Data: Mixed Methods Study

Background: Patient recruitment remains a critical challenge in clinical research. Although the integration of electronically collected patient-entered data within clinical practices enables innovative recruitment approaches, existing methods present challenges such as increased patient burden and potential violation of autonomy. A more nuanced approach involves identifying patient attributes associated with higher propensity for research participation, enabling research teams to efficiently prioritize outreach efforts. Objective: This study aims to (1) develop patient-reported questions reflecting perceptions about research participation and (2) determine whether patient responses are predictive of interest in joining a precision medicine registry. Methods: This mixed methods study used an exploratory sequential design in 2 phases. Phase 1 involved cognitive interviews with 32 patients recruited through the Cleveland Clinic Healthcare Partners program to develop “research perception” questions. Participants evaluated 9 candidate questions that were based on a literature review of research participation factors. Three questions were selected for implementation. Phase 2 was a cross-sectional cohort study incorporating these 3 questions into routine electronic questionnaires completed by primary care patients through the patient portal. The study population included 1077 patients who completed both “research perception” and “research recruitment” questions between August 2018 and April 2019. Diagnostic accuracy was assessed using receiver operating characteristic curve analysis, and multivariable logistic regression models evaluated associations while adjusting for demographic and health factors. Results: Phase 1 revealed strong research support among participants, with 97% (31/32) agreeing that research should be part of the institution’s mission and 100% (32/32) affirming that research enhances patient care. Phase 2 included 1077 patients (mean age 48.3, SD 16.3 years; 625/1065 female, 58.68%; 661/1005 White, 65.77%), of whom 278 (25.8%) expressed interest in being contacted about the precision medicine registry. Patients expressing interest were older and had worse self-reported health, more depressive symptoms, and greater social needs. “Strongly agree” and “very important” responses to any “research perception” question were significantly associated with study interest, with adjusted odds ratios ranging from 6.36 (95% CI 2.77-14.6) to 17.6 (95% CI 5.08-61.1; P<.001). The “research perception” questions demonstrated high sensitivity (>80%) but limited specificity (24%-31%). Conclusions: Patient-reported questions assessing research participation likelihood can help identify patients more likely to enroll in clinical studies. This approach enables effective recruitment prioritization while preserving patient autonomy and reducing patient burden. High sensitivity makes these questions valuable as screening tools, although limited specificity suggests use for prioritizing rather than excluding participants. Further validation across different trial types and populations is warranted.
❌